2025 ESMO Asia congress

Neoadjuvant (neoadj) osimertinib (osi) ± chemotherapy (CT) vs CT alone in patients (pts) with resectable epidermal growth factor receptor-mutated (EGFRm) stage II?IIIB non-small cell lung cancer (NSCLC): Patient-reported outcomes (PROs) from NeoADAURA

2025

2025 KALC international conference

Comparative Risk of Neurological Adverse Events Between PD-1 and PD-L1 Inhibitors in Korean Lung Cancer Patients: A Nationwide Cohort Study

2025

2025 KALC international conference

Predictive Value of Inflammatory Biomarkers in EGFR-Mutant NSCLC Treated with Lazertinib: An Interim Analysis of a Prospective Real-World Study (ORIENT)

2025

2025 KALC international conference

Risk and Incidence of Drug-Induced Interstitial Lung Disease Associated with Anti-Neoplastic Therapy: A Nationwide Population-Based Study in Korea

2025

2025 KALC international conference

Clinical Relevance of Pleural Tissue Debris Incidentally Obtained During Catheter Drainage for Pleural Effusion

2025